Our R&D portfolio consists of antiviral compounds. What makes us unique is our chemical process technology for the thionation of drug molecules, JBR, named after our co-founder Jan Bergman, Late Prof. Emeritus at the Karolinska Institute in Stockholm. Prof. Bergman has played a significant role in the development of Vironova Medical with extensive experience in organic molecules and their application in drug design.